Ryght AI's Free Site Search: Your Site Is Being Ranked, Whether You Take Part or Not
Published November 2026 — In April 2026, Ryght AI launched a free search engine that ranks clinical trial sites worldwide, and in May ASCO began using Ryght's platform to choose sites for a breast cancer study. Sites are now being profiled and ranked from data they did not supply.
Site Search Becomes Free and Public
On April 16, 2026, Ryght AI launched RyghtSites.com, which it describes as a free tool for sponsors and CROs to search, rank, and download lists of clinical trial sites. Users can filter by disease, biomarker, and region, and results are ranked by what the company calls feasibility and fit and real-world trial history.
On May 28, 2026, ASCO announced that it is using Ryght's platform to identify and activate sites for a study of CDK4/6 inhibitor dosing in metastatic breast cancer. Together the two announcements show a change that affects every site: sponsors can now form a view of a site before they contact it.
Key Findings
Ryght says its search covers 100,000 site locations in 192 countries. This is the company's own figure.
The company says it has built more than 60,000 digital profiles of sites, drawing on more than 450,000 trials and 145,000 principal investigators.
Ryght reports that an unnamed global CRO identified 43 qualified sites for an early-phase oncology trial in 26 days, against a target of 13. This is a vendor claim about sites identified, not patients enrolled.
In the same account, the first completed feasibility questionnaire came back in 35 minutes. Speed of response is now visible to the sponsor.
What This Changes for Sites
The details of how these profiles are built are not fully public, which is part of the point.
Profiles Built Without the Site
Ryght's announcements do not list what a site's profile contains or name the sources behind it, beyond trial and investigator records. Nothing in the launch materials says a site can claim or correct its public listing. A site's first impression may be formed from records it has never reviewed.
How Matching Works
In the ASCO announcement, the platform is described as matching a protocol to sites on investigator expertise, operational capacity, prior performance, patient access, competing trials, and regulatory history. Those are the dimensions on which a site is now being compared.
Where Sites Do Get a Say
Ryght has said that in its paid feasibility product, sites can review, confirm, and update pre-filled answers, and that their responses feed back into their profile. H1, which launched a competing product in April 2026, says sites can claim and manage their profiles. The feasibility response is becoming the main point at which a site can correct the record.
A Note of Caution
Being identified is not the same as being activated. One commentator observed that identification is the algorithm's job and activation is still the site's, citing a median activation time of 167 days at cancer centers against a 90-day target. A good ranking only helps a site that can start quickly.
What This Means for Sites
Sites cannot opt out of being ranked. They can influence what the ranking is based on.
Review how your site and investigators appear in public registries and trial listings. Names, addresses, and study records that are inconsistent or out of date are what an algorithm will find.
When a questionnaire arrives pre-filled, the review is your chance to fix it. Accurate, specific, well-evidenced answers now shape your profile as well as the study decision.
Response time is measured and reported to sponsors. A site that takes a week to answer is now compared with one that took an hour.
Conclusions
Free, public site search lowers the cost for a sponsor of looking beyond the sites it already knows. That is an opportunity for capable sites that have been hard to find.
It also means a site's reputation is increasingly assembled by others from public data. Sites that keep their record accurate, answer feasibility requests quickly, and can show verified performance will be better placed than those that wait to be asked.
See What the Data Says, and Answer Faster
A free SiteScore™ PreScore shows a site how it looks from public data alone, which is the view an outside algorithm starts from. A Validated Score replaces that view with one checked against the site's own documents and gives the site a sponsor-visible profile and an improvement roadmap.
FeasComplete™ addresses the other half. It keeps one accurate site profile, drafts feasibility responses from it, and routes questions to the right person with a deadline, so the site's answers are consistent and arrive quickly.
This industry case study is based on published announcements and industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative. Companies named are not Clinitiative clients unless stated.
- Ryght AI: Introducing RyghtSites.com (April 16, 2026)
- Ryght AI: How a global CRO compressed six months of site selection into 26 days (March 11, 2026)
- ASCO using Ryght AI's platform to accelerate site selection for breast cancer clinical trial (May 28, 2026)
- The ASCO Post: ASCO collaborates with Ryght AI
- Ryght AI blog: Rethinking clinical trial site selection (October 2, 2026)
- H1 launches Site Network Suite (April 23, 2026)
- Clinical Trial Vanguard: AI site selection sounds fast until you see what happens after the algorithm picks your site (June 4, 2026)
Win the Study, Then Prove the Performance
FeasComplete™ helps sites answer feasibility requests faster. SiteScore™ verifies and benchmarks how they perform.